EUCTR2009-015833-66-IT进行中(未招募)不适用
Ropinirole 24h prolonged release and motor fluctuations: a study to control the wearing-off induced by dopamine agonists immediate release
CASA DI CURA PRIVATA S.RAFFAELE - PISANA0 个研究点开始时间: 2012年4月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A subject will be eligible for inclusion in this study only if all of the following criteria apply: Diagnosis of idiopathic Parkinson’s disease (according to modified Hoehn & Yahr criteria Stages I-IV) Subjects ia a stable DA agonists dose regimen for at least 18 months Subjects provided written informed consent for the study. Subjects are willing and able to comply with study procedures, including diary card completion and follow-up clinic visits.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1. Late stage advanced subjects demonstrating incapacitating dyskinesias 2. Presence, or history within the previous 3 months, of significant and/or uncontrolled psychiatric, haematological, renal, hepatic, endocrinological, neurological (other than Parkinson’s disease), or cardiovascular disease or active malignancy (other than basal cell cancer). 3. Any abnormality, at screening, that the investigator deems to be clinically relevant on history, physical examination and in diagnostic laboratory tests including ECG. 4. Recent history of severe dizziness or fainting due to postural hypotension on standing. 5. Clinical dementia that in the judgment of the investigator would preclude assessment of the subject. 6. Subjects with neurotic behaviour, crippling degenerative arthritis or limb amputations, which would preclude efficacy or safety assessments. 7. Subjects with prior or current major psychosis (e.g. schizophrenia or psychotic depression) e.g., scoring 3 or 4 on UPDRS item 2 (thought disorder) or item 3 (depression). 8. Recent history or current evidence of drug abuse or alcoholism.
研究者
相似试验
进行中(未招募)
不适用
Early combined prolonged release ropinirole and rasagiline therapy in newly diagnosed patients with Parkinsons disease. A prospective, randomized, parallel groups, long-term follow-up study including delayed-start design of rasagiline - Early combined ropinirole and rasagiline therapy in patients with Parkinsons diseasePatients with Parkinson`s dieseaseMedDRA version: 12.0Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2009-013004-31-ITIVERSITA` DEGLI STUDI DI PARMA
进行中(未招募)
不适用
24-hour IOP control with Travoprost / Brinzolamide fixed combination once-daily (QD)in the evening vs TRAVATAN - 24-hour IOP-lowering effect of Travoprost/BrinzolamideOpen-angle glaucoma or ocular hypertensionMedDRA version: 9.1Level: SOCClassification code 10015919Term: Eye disordersMedDRA version: 9.1Level: LLTClassification code 10030348Term: Open angle glaucomaMedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionEUCTR2008-002750-38-ITAlcon Research Ltd
进行中(未招募)
不适用
Propiverine hydrochloride extended release (ER): Tolerability in patients with LUTS and BPS/BPHA randomised, double-blind, placebo-controlled, multi-centre clinical trial - not applicableEUCTR2004-000871-33-CZApogepha Arzneimittel GmbH120
已完成
3 期
urasidone - A 24-week Extension Study of Patients With Bipolar I DepressioCTRI/2009/091/000752Sunovion Pharmaceuticals Inc460
进行中(未招募)
1 期
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I DepressioEUCTR2008-007483-42-FRDainippon Sumitomo Pharma America Inc.460
